A Lawsuit Unfolds: States Target Cord Blood Registry
Attorneys general from Texas and Arizona have jointly filed a significant lawsuit against Cord Blood Registry (CBR), a prominent private cord blood banking company, alleging that it engaged in widespread false advertising and deceptive practices to profit from new and expectant parents. The lawsuit, filed on October 26, 2023, in a Travis County District Court in Texas, contends that CBR, a subsidiary of CooperSurgical, exploited the emotional vulnerability of parents by making exaggerated claims about the medical utility and necessity of storing umbilical cord blood stem cells.
Texas Attorney General Ken Paxton and Arizona Attorney General Kris Mayes announced the legal action, emphasizing their commitment to consumer protection in the healthcare sector. “New parents, often overwhelmed and seeking the best for their children, are particularly susceptible to misleading claims,” said Paxton in a press statement. “Our investigation revealed a pattern of deceptive marketing by Cord Blood Registry that misrepresented the likelihood of medical use and the scope of treatable conditions, effectively selling a biological insurance policy that rarely pays out.”
Attorney General Mayes echoed these sentiments, highlighting the financial burden placed on families. “Families pay substantial fees for these services, often under the impression they are securing a vital health resource for their child’s future. When those promises are overblown or outright false, it constitutes a serious breach of trust and consumer fraud.”
The Promise and Peril of Cord Blood Banking
Cord blood banking involves collecting blood from a newborn's umbilical cord and placenta after birth, which is rich in hematopoietic stem cells. These cells have the potential to treat certain blood and immune system disorders, such as leukemia, lymphoma, and some genetic diseases. Private cord blood banks, like CBR, store these cells for a fee, making them available exclusively to the donor child or compatible family members. Public cord blood banks, by contrast, store donations for use by anyone who needs a match.
The decision to bank cord blood is complex, involving significant upfront costs—often ranging from $1,500 to $2,000 for collection and processing—followed by annual storage fees that can exceed $180. While the medical potential of cord blood is real, its utilization rate, particularly for a child's own (autologous) use, remains remarkably low, estimated to be less than 1% over a lifetime. Critics argue that private cord blood banks often fail to adequately disclose this low probability, instead focusing on emotionally charged narratives of potential life-saving treatments.
Allegations of Deception: Targeting Vulnerable Parents
The lawsuit details several specific instances of alleged false advertising by CBR. According to the attorneys general, CBR's marketing materials—including brochures, website content, and social media campaigns—routinely:
- Exaggerated the likelihood of use: Claims suggested cord blood was a “biological safety net” or “guaranteed protection” against a wide array of future diseases, despite the extremely low probability of a child needing their own stored cells.
- Misrepresented treatable conditions: CBR allegedly implied that cord blood could effectively treat over 100 conditions, without adequately distinguishing between conditions where autologous (self) cord blood is standard treatment versus those where it's experimental, or where allogeneic (donor) cord blood is typically preferred.
- Failed to disclose limitations: The company purportedly downplayed the fact that stored cord blood might not be viable or sufficient for treatment, or that genetic conditions present at birth could also be present in the cord blood, limiting its utility.
- Used emotionally manipulative language: Marketing tactics were designed to induce fear and urgency in new parents, suggesting that not banking cord blood meant missing a crucial, once-in-a-lifetime opportunity to safeguard their child’s health.
The states' investigation reportedly uncovered internal documents and marketing scripts used by CBR sales representatives that prioritized emotional appeals over factual medical accuracy. One alleged example cited in the lawsuit involved a brochure stating, “Don’t regret missing the chance to protect your child’s future health,” directly alongside a list of dozens of conditions, without proper context regarding treatment efficacy or probability of use.
Seeking Restitution and Industry Reform
The lawsuit seeks significant relief, including permanent injunctions to prevent CBR from continuing its deceptive practices, substantial civil penalties of millions of dollars for each state, and full restitution for consumers who were misled by the company’s advertising. The attorneys general are also pushing for mandatory changes in CBR’s marketing and disclosure practices, requiring clear, unambiguous information about the actual probabilities of use, the costs involved, and the medical limitations of cord blood banking.
In response to the lawsuit, Dr. Evelyn Reed, Chief Medical Officer at Cord Blood Registry, issued a statement acknowledging the legal action. “Cord Blood Registry is committed to transparency and providing accurate information to families. We are reviewing the allegations made by the attorneys general of Texas and Arizona and are prepared to cooperate fully to address their concerns. Our mission remains to provide innovative services that can potentially benefit families, and we stand by the integrity of our operations.”
This legal challenge marks a critical moment for the private cord blood banking industry, potentially setting a precedent for how such services are marketed to vulnerable populations. Consumer advocates hope the lawsuit will lead to greater clarity and ethical standards, ensuring that parents can make informed decisions about their children’s health without being swayed by misleading promises.
